Clofazimine is primarily used in the treatment of leprosy, particularly multidrug-resistant forms, as part of multidrug therapy regimens. It has strong anti-inflammatory properties, making it useful in managing leprosy-related skin reactions such as erythema nodosum leprosum (ENL). The drug accumulates in macrophages and helps reduce the bacterial load by targeting Mycobacterium leprae. It has also been repurposed for treating multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant TB (XDR-TB) due to its antimicrobial activity against mycobacteria. More recently, clofazimine has shown potential in research for inflammatory and autoimmune conditions because of its immunomodulatory effects. Additionally, it is being explored for its antiviral properties, including activity against certain enveloped viruses, though such uses remain under investigation.